WallStreetZenWallStreetZen

NASDAQ: KPTI
Karyopharm Therapeutics Inc Stock Ownership - Who owns Karyopharm Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Karyopharm Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Kristin AbateChief Accounting Officer2025-09-0312$6.78
$81.36Sell
Stuart PoultonEVP Chief Development Officer2025-07-29191$4.37
$834.67Sell
Kristin AbateChief Accounting Officer2025-07-22238$4.00
$952.00Sell
Richard A. PaulsonPresident and CEO2025-05-06236$7.12
$1.68kSell
Reshma RangwalaEVP Chief Medical Officer2025-04-23419$6.17
$2.59kSell
Richard A. PaulsonPresident and CEO2025-04-04245$3.74
$916.30Sell
Kristin AbateChief Accounting Officer2025-03-04571$6.29
$3.59kSell
Sohanya Roshan ChengEVP Chief Commercial Officer2025-03-043,445$6.29
$21.67kSell
Michael ManoSVP General CounselSecretary2025-03-042,793$6.29
$17.57kSell
Richard A. PaulsonPresident and CEO2025-03-0411,694$6.29
$73.56kSell

1 of 2

KPTI insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when KPTI insiders and whales buy or sell their stock.

KPTI Shareholders

What type of owners hold Karyopharm Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Chione Ltd187.49%16,258,079$104.86MInsider
Plio Ltd73.08%6,336,946$40.87MInsider
Marcin Czernik68.40%5,930,939$38.25MInsider
Deepika Pakianathan26.33%2,283,343$14.73MInsider
Sharon Shacham19.28%1,671,888$10.78MInsider
Michael Kauffman18.59%1,611,888$10.40MInsider
T Rowe Price Investment Management Inc8.40%728,766$4.70MInstitution
Vanguard Group Inc5.98%518,269$3.34MInstitution
Adage Capital Partners GP LLC4.86%421,322$2.72MInstitution
Michael Mason4.51%391,054$2.52MInsider

1 of 3

KPTI vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
KPTI11.06%88.94%Net SellingNet Selling
PDSB15.86%25.35%Net Buying
ICCC14.47%21.19%Net Buying
GNTA2.94%0.00%
CAMP40.59%59.41%Net BuyingNet Buying
View Top Biotech Stocks

Karyopharm Therapeutics Stock Ownership FAQ

Who owns Karyopharm Therapeutics?

Karyopharm Therapeutics (NASDAQ: KPTI) is owned by 50.89% institutional shareholders, 409.37% Karyopharm Therapeutics insiders, and 0.00% retail investors. Chione Ltd is the largest individual Karyopharm Therapeutics shareholder, owning 16.26M shares representing 187.49% of the company. Chione Ltd's Karyopharm Therapeutics shares are currently valued at $101.78M.

If you're new to stock investing, here's how to buy Karyopharm Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.